WET AGE RELATED MACULAR DEGENERATION
Clinical trials for WET AGE RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new WET AGE RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for WET AGE RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug shows promise in battle against blinding disease
Disease control CompletedThis study tested a new medicine called JL14002 against a standard treatment (ranibizumab) for wet age-related macular degeneration, a leading cause of vision loss. 443 adults aged 50-80 took part. The main goal was to see if the new drug could improve vision as well as the stand…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
New eye drug could mean fewer shots for wet AMD patients
Disease control CompletedThis study tested a new eye injection called EYP-1901 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal was to see if EYP-1901 could control the disease as well as the standard treatment aflibercept, but with fewer injections. Th…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
New eye drops aim to tackle blinding disease – first safety check in humans
Disease control CompletedThis early-stage study tested whether SCAI-005 eye drops are safe and how they move through the body in 48 healthy Korean adults. The goal is to develop a convenient eye drop treatment for wet age-related macular degeneration, a leading cause of vision loss. No results are availa…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Phase: PHASE1 • Sponsor: SCAI Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
AI Eye-Tracker could let macular disease patients skip clinic visits
Knowledge-focused CompletedThis study tested a new, low-cost eye-tracking system called CRYSTALSIGHT that uses artificial intelligence to monitor macular diseases like age-related macular degeneration and diabetic retinopathy. Twenty participants used the device at home to track eye movements, and research…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Sponsor: Tan Tock Seng Hospital • Aim: Knowledge-focused
Last updated May 17, 2026 05:49 UTC